Search Within

Dana Elizabeth Rathkopf

  1. "Radiation Oncology, Department of"
Formats
  1. Meeting Abstract (11)
  2. Journal Article (3)
Groups
  1. Department of Medicine (14)
  2. Genitourinary Oncology Service (14)
  3. Radiation Oncology, Department of (14)
  4. Solid Tumor Oncology Division (14)
  5. GDMT, Radiation Oncology (9)
  6. Gynecology Disease Management Team (9)

More Groups

People
  1. Marisa Kollmeier (9)
  2. Sean McBride (8)
  3. Howard Scher (5)
  4. Han Xiao (4)
  5. Susan Slovin (4)
  6. Wassim Abida (4)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (2)
  4. 2022 (2)
  5. 2021 (3)
  6. 2019 (1)

More Years

Publications
  1. Journal of Clinical Oncology (6)
  2. International Journal of Radiation Oncology, Biology, Physics (3)
  3. Annals of Oncology (2)
  4. Clinical Cancer Research (1)
  5. Journal of Urology (1)
  6. Prostate (1)
Publishers
  1. American Society of Clinical Oncology (6)
  2. Elsevier Inc. (3)
  3. Oxford University Press (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Science, Inc. (1)
  6. John Wiley & Sons (1)

Results (14)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • National cancer system characteristics and prostate cancer outcomes: An analysis of global data
    Journal Article

    Dee, E. C.; Iyengar, R.; Narayan, A.; Feliciano, E. J. G.; Wu, J. F.; Ho, F. D. V.; Ng, K.; Willmann, J.; Cabaero, M. L. L.; Tan, A. K. N. G.; more...
    Prostate (2025)

    Fulltext@MSK | Save
  • SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
    Meeting Abstract

    Rathkopf, D.; Dallos, M.; Stein, M.; Spina, C. S.; Deutsch, I.; Nguyen, C.; Okada, A.; Lloyd, M.; Manarite, J.; McBride, S.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Long-term patient-reported health-related quality of life in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH Agonist with either bicalutamide or abiraterone acetate plus prednisone and apalutamide after radical prostatectomy
    Meeting Abstract

    Hoffman, K. E.; Nguyen, P. L.; Rathkopf, D.; Zurita-Saavedra, A.; Spratt, D. E.; Dess, R. T.; Liauw, S.; Szmulewitz, R.; Einstein, D. J.; Bubley, G.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Testosterone Recovery and Associated Impact on PatientReported Health -Related Quality of Life (HRQoL) after Treatment with 6 Months of GnRH Agonist with or without Abiraterone Acetate plus Prednisone (AAP) and Apalutamide (Apa) in the FORMULA-509 Trial
    Meeting Abstract

    Moningi, S.; Nguyen, P. L.; Rathkopf, D.; Zurita-Saavedra, A.; Spratt, D. E.; Dess, R. T.; Liauw, S.; Szmulewitz, R.; Einstein, D. J.; Bubley, G.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP)
    Meeting Abstract

    Hoffman, K. E.; Nguyen, P. L.; Rathkopf, D. E.; Zurita, A. J.; Spratt, D. E.; Dess, R. T.; Liauw, S. L.; Szmulewitz, R. Z.; Einstein, D. J.; Bubley, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)
    Meeting Abstract

    Nguyen, P. L.; Kollmeier, M. A.; Rathkopf, D.; Hoffman, K. E.; Zurita-Saavedra, A.; Spratt, D. E.; Dess, R. T.; Liauw, S.; Szmulewitz, R.; Einstein, D. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)
    Meeting Abstract

    Nguyen, P. L.; Kollmeier, M.; Rathkopf, D. E.; Hoffman, K. E.; Zurita, A. J.; Spratt, D. E.; Dess, R. T.; Liauw, S. L.; Szmulewitz, R. Z.; Einstein, D. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Dermatological adverse events in prostate cancer patients treated with the androgen receptor inhibitor apalutamide
    Journal Article

    Pan, A.; Reingold, R. E.; Zhao, J. L.; Moy, A.; Kraehenbuehl, L.; Dranitsaris, G.; McBride, S. M.; Scher, H. I.; Kollmeier, M. A.; Xiao, H.; more...
    Journal of Urology (2022)

    Fulltext@MSK | Save
  • Differences in prostate cancer genomes by self-reported race: Contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors
    Journal Article

    Stopsack, K. H.; Nandakumar, S.; Arora, K.; Nguyen, B.; Vasselman, S. E.; Nweji, B.; McBride, S. M.; Morris, M. J.; Rathkopf, D. E.; Slovin, S. F.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Interim results of AASUR: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA plus P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa)
    Meeting Abstract

    McBride, S. M.; Spratt, D. E.; Kollmeier, M.; Abida, W.; Xiao, H.; Slovin, S. F.; Paller, C. J.; Deville, C.; Den, R. B.; Hearn, J. W. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save